Community-associated MRSA: new guidelines for a new age.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Susan Simmons Holcomb.
Explore the source record for details and available documents.
PURPOSE: To provide the physician and registered professional nurse with an overview of the pathophysiology and the care of patients with lymphedema. TARGET AUDIENCE: This continuing education activity is intended for physicians and nurses with an interest in learning more about the different types of lymphedema and the appropriate treatment strategies. OBJECTIVES: After reading the article and taking the test, the participant should be able to: 1. Identify the types of lymphedema, their causes, and possible complications. 2. Describe the diagnostic criteria, preventive strategies, and treatment strategies for lymphedema.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Type 2 diabetes mellitus (DM2) has increased 41% in the United States, with an estimated one third undiagnosed and another 41 million with prediabetes. Hypertension affects 20% to 60% of all diabetics, contributing to up to 75% of deaths due to cardiovascular disease. These staggering statistics make it imperative that hypertensive patients who are at risk for DM2 are identified and treated early. Numerous studies have been done involving choice of antihypertensive in established diabetics, and a slowing or halting of the progression in the development of diabetes in these patients has been noticed. However, to date, nothing is conclusive. For now, following the JNC 7 guidelines of using a diuretic as monotherapy or in combination with an angiotensin-converting enzyme inhibitor (ACEI), angiotensin II-receptor blocker (ARB), beta-blocker, or calcium channel blocker may be prudent. Two current studies, the DREAM trial and the ONTARGET trial, may shed more light as to whether ACEIs or ARBs have a preferred niche in initial treatment of the hypertensive patient who is at risk for diabetes.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
New therapies improve the management of pulmonary arterial hypertension.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.